Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in New Haven CT, developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC).
Stock Option Grants, 401(k) with Company Match, Hybrid Schedule, Employee Stock Purchase Plan, Company Paid Life and Accidental Death & Dismemberment Coverage, Paid Parental Leave
